Clinical-stage gene editing firm Precision BioSciences Inc (DTIL) is scheduled to release its first-quarter 2026 financial report before the market opens on Tuesday, May 6, followed by a conference call at 9:30 a.m.

Market expectations indicate that analysts forecast a per-share loss between $0.655 and $0.81 for the first quarter, with revenue estimated at approximately $4.05 million. It is noteworthy that the company has surpassed earnings per share estimates four times over the past year, achieving a beat rate of 75%, which reflects strong cost management capabilities. However, regarding revenue performance, the company has exceeded market expectations only once in the same period, representing a 25% beat rate.

Looking back at the previous quarter, the company's performance showed a mixed picture: revenue for the fourth quarter of 2025 reached $34.2 million, significantly surpassing the market consensus of $9.075 million, but this was largely driven by a one-time milestone payment. The company's proprietary ARCUS gene editing platform, which focuses on in vivo and ex vivo gene therapies, recently extended its cash reserves into 2027 through the addition of a priority review voucher.

Recent insider transactions have drawn attention: CEO Michael Amoroso and CFO John Alexander Kelly sold 20,559 shares and 8,149 shares, respectively, on February 18, at an average price of $3.84 per share. Analysts maintain a "Moderate Buy" rating on the stock, with an average price target of $36.33, suggesting significant potential upside from the current share price.